Statins reduced risk for hypoxic hepatitis in ICU patients

Drolz A. J Hepatol. 2014;doi:10.1016/j.jhep.2014.01.019.

  • March 3, 2014

Statin therapy received before ICU admission reduced the risk for hypoxic hepatitis, a potentially deadly complication, in critically ill patients, according to study data.

A prospective study of three ICUs at Medical University of Vienna in Austria included 851 consecutive patients (mean age, 63 years; 60% men) who had been screened for hypoxic hepatitis (HH) within 2 days of ICU admission. Fifty-five percent of the patients were admitted because of cardiogenic events and/or cardiopulmonary resuscitation or infections/sepsis.

Before admission, 155 patients (18%) had received statins for hepatic ischemia or hepatic reperfusion. Atorvastatin (45%) and simvastatin (43%) were the most commonly used drugs. Researchers documented the 28-day, 90-day, and 1-year survival rates for all patients.

Among the statin patients, 95% did not develop HH (n=147), while the other eight and 79 patients not receiving statins developed HH within 48 hours of ICU admission.

Of the study patients admitted to the ICU, 26% died within 28 days, 33% died within 90 days and the remainder died within 1 year. For each period mortality rates in HH were 58%, 67% and 74%, respectively.

In multivariate analysis, patients treated with statins before ICU admission displayed a significant association with decreased incidence of HH within 48 hours of admission (adjusted OR=0.42; 95% CI, 0.19-0.95). This effect was only significant for improved survival at 28 days (P<.05), but not 90-day or 1-year mortality.

Independent risk factors that increased the odds for HH were cardiogenic shock (aOR=6.88; 95% CI, 3.95-11.96), septic shock (aOR=3.46; 95% CI, 1.95-6.14) and active alcohol consumption (aOR=3.33; 95% CI, 1.41-7.85).

“This is the first study prospectively evaluating risk and protective factors for new onset of HH within 48 hours after ICU admission,” the researchers wrote. “Statin therapy led to a significant reduction of new onset of HH at the ICU.”

Disclosure: The researchers report no relevant financial disclosures.


Healio is intended for health care provider use and all comments will be posted at the discretion of the editors. We reserve the right not to post any comments with unsolicited information about medical devices or other products. At no time will Healio be used for medical advice to patients.